Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Rated “Moderate Buy” by Sell-Side Analysts

by · The Markets Daily

Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $35.33.

Several brokerages have weighed in on ODTX. Weiss Ratings began coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. JPMorgan Chase & Co. raised their price objective on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Raymond James Financial began coverage on Odyssey Therapeutics in a report on Thursday, October 8th. They issued an “outperform” rating and a $42.00 target price for the company. HC Wainwright started coverage on Odyssey Therapeutics in a research report on Thursday, August 27th. They set a “buy” rating and a $44.00 target price on the stock. Finally, UBS Group initiated coverage on Odyssey Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $27.00 price target for the company.

Get Our Latest Report on Odyssey Therapeutics

Odyssey Therapeutics Stock Up 10.4%

ODTX stock opened at $21.57 on Friday. The firm has a fifty day simple moving average of $21.58. Odyssey Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. Analysts predict that Odyssey Therapeutics will post -6.08 earnings per share for the current year.

Institutional Investors Weigh In On Odyssey Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ODTX. State Street Corp purchased a new position in Odyssey Therapeutics during the 2nd quarter valued at $1,477,000. The Manufacturers Life Insurance Company purchased a new stake in Odyssey Therapeutics in the 2nd quarter valued at about $601,000. Finally, Citadel Advisors LLC purchased a new stake in Odyssey Therapeutics in the 2nd quarter valued at about $4,162,000.

Odyssey Therapeutics Company Profile

(Get Free Report)

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.

See Also